載入中
NASDAQHealthcareBiotechnology
最新資料
US$143.73
+US$3.82 · +2.73%
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
前收盤價
US$143.73
+US$3.82 · +2.73%
盤中時間採用ET。市場資料可能有所延遲。
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
日內區間
目前US$143.73
52週區間
目前US$143.73
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
2
估值過高
情緒
59
多空交錯
風險
46
風險偏高
動能
80
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
日內區間
目前US$143.73
52週區間
目前US$143.73
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4601.6萬 USD | 4.34億 USD | 6000萬 USD | 2658.1萬 USD | 2735.7萬 USD |
| 銷貨成本 | 122.5萬 USD | — | — | — | — |
| 毛利 | 4479.1萬 USD | 4.34億 USD | 6000萬 USD | 2658.1萬 USD | 2735.7萬 USD |
| 研究與開發 | 1.59億 USD | 1.38億 USD | 1.2億 USD | 1.26億 USD | 1.26億 USD |
| 銷售、一般及管理費用 | 4485.3萬 USD | 4346.2萬 USD | 3349.1萬 USD | 3173.9萬 USD | 2719.6萬 USD |
| 營業費用 | 2.03億 USD | 1.82億 USD | 1.54億 USD | 1.58億 USD | 1.53億 USD |
| 利息收入 | 2878.9萬 USD | 2631.5萬 USD | 1489.8萬 USD | 406萬 USD | 44.3萬 USD |
| 折舊和攤銷 | 128萬 USD | 296.3萬 USD | 331.2萬 USD | 336.9萬 USD | 277.5萬 USD |
| 營業利益 | −1.58億 USD | 2.53億 USD | −9365.2萬 USD | −1.31億 USD | −1.26億 USD |
| 淨利 | −1.3億 USD | 2.75億 USD | −7895.5萬 USD | −1.27億 USD | −1.26億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$176.29
上漲空間 22.65%報告持有此股票曝險的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR5.41億0.52%1031.91億 USD0.06%US$137.55—
Vanguard Morningstar Total Stock Market ETFVTI3.03億0.01%2.3兆 USD0.03%US$381.94—
iShares Russell 2000 ETFIWM2.27億0.29%787.4億 USD0.19%US$278.94—
Vanguard Morningstar Small-Cap ETFVB2.19億0.12%1853億 USD0.03%US$289.48—
State Street SPDR S&P Biotech ETFXBI1.44億1.46%98.74億 USD0.35%US$153.77—
Vanguard Morningstar Small-Cap Growth ETFVBK1.25億0.27%447億 USD0.05%US$344.74—
Vanguard Extended Market ETFVXF1.04億0.11%954億 USD0.05%US$235—
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM8319.16萬0.53%158.4億 USD0.03%US$53.45—iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
